Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1Appendiceal Neoplasms 1

Interventions

Oxaliplatin 5Leucovorin 5Capecitabine 5Fluorouracil 4Erlotinib Hydrochloride 4Trastuzumab 3trametinib 2pembrolizumab 2Sorafenib 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Interleukin-12 Subunit p35 2Gemcitabine 2Floxuridine 2Chemotherapy, Adjuvant 2AZD 6244 2tremelimumab 1tivozanib 1tipifarnib 1motexafin lutetium 1ixabepilone 1entinostat 1durvalumab 1dehydroftorafur 1cediranib 1Watchful Waiting 1Specimen Handling 1Radiotherapy 1Radiofrequency Ablation 1Phototherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bile Duct Neoplasms × motexafin lutetium × Clear all
NCT00087191 2013-01-16

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Terminated
30 enrolled
GastrointestinalGynecologicSarcomaThoracic

Carcinoma, Ovarian Epithelial, Appendiceal Neoplasms, Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡